Caricamento...
Carfilzomib for relapsed and refractory multiple myeloma
Although the prognosis of multiple myeloma (MM) patients has dramatically improved during recent years, virtually all patients eventually develop relapsed refractory disease. Several new therapeutics have been developed in the last few years, including carfilzomib, a second-generation proteasome inh...
Salvato in:
| Pubblicato in: | Cancer Manag Res |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Dove Medical Press
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6450182/ https://ncbi.nlm.nih.gov/pubmed/31037034 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CMAR.S150653 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|